Compare ASRT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | PYXS |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 71.6M |
| IPO Year | 1997 | 2021 |
| Metric | ASRT | PYXS |
|---|---|---|
| Price | $12.07 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $35.00 | $6.75 |
| AVG Volume (30 Days) | 53.9K | ★ 1.2M |
| Earning Date | 03-11-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,354,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $7.71 | $0.83 |
| 52 Week High | $15.15 | $5.55 |
| Indicator | ASRT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 36.12 |
| Support Level | $11.43 | $1.38 |
| Resistance Level | $12.95 | $1.69 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 52.41 | 10.69 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.